XyloCor Therapeutics
Manufacturing · Pennsylvania, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
39 Addison Ln, Malvern, Pennsylvania, 19...Phone Number
(888) 290-0081Website
www.xylocor.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
1
1
1
1
1
1
About XyloCor Therapeutics
XyloCor Therapeutics is a biopharmaceutical company focused on the development of novel gene therapy for unmet needs in advanced coronary artery disease. Established in 2013, XyloCor Therapeutics is headquartered in Pennsylvania, United States.Explore more
XyloCor Therapeutics Org Chart
Get the full picture
Sign in to uncover key details.
Show More
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is XyloCor Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check if XyloCor Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Website visits: Recent activity has been detected on your website
Congratulate Masked Content for being promoted to Masked Content at XyloCor Therapeutics
Click to see if XyloCor Therapeutics had a recent Job posting/layoffs
Check out if XyloCor Therapeutics is spiking on competitors!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Funding: Get notified immidiatlly once XyloCor Therapeutics has new funding data
Product Launch: Get notified when XyloCor Therapeutics launches new products
XyloCor Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Earning: See what the market has to say on XyloCor Therapeutics recently announced quarterly report
Recommended Actions
Reach out to Masked Content who joined XyloCor Therapeutics as Masked Content
Find 3 more new buyers
Compare Similar Companies to XyloCor Therapeutics
Compare insights from companies similar to XyloCor Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
XyloCor Therapeutics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
XyloCor Therapeutics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about XyloCor Therapeutics.
XyloCor Therapeutics financials insights
Gather financial insights about XyloCor Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2018
Series A
$17M
2021
Other Financing Round
$22.6M
XyloCor Therapeutics Tech Stack
A closer look at the technologies used by XyloCor Therapeutics
Most Recent Scoops
New Hire
Executive Move
Executive Moves, New Hire
Left Company
Executive Move
Executive Moves, Left Company
Funding
Project
Award, Spending/Investment
New Hire
Executive Move
New Hire
Executive Move
XyloCor Therapeutics News & Media
Jeito Capital leads $67.5 million (€64.4 million[1]) Series B financing in XyloCor Therapeutics to develop Novel Gene Therapy in Cardiovascular Disease
Jeito Capital leads $67.5 million (€64.4 million1) Series B financing in XyloCor Therapeutics to develop Novel Gene Therapy in Cardiovascular DiseaseXyloCor and SmartCella enter into license agreement for use of the Extroducer to administer novel gene therapy XC001 to the heart
· The Extroducer® Infusion Catheter System ® enables local delivery of XC001 to the heart without the need for surgery. · XC001 has achieved positive Phase 1/2 results in the EXACT Trial validating its transformative potential for treatment of refractory angina in patients who have exhausted available treatment options and have a debilitating quality-of-life. Wayne, PA, and Tullinge, Sweden July 10, 2024 —XyloCor Therapeutics, Inc. (“XyloCor”), a clinical‑stage biopharmaceutical company developiXyloCor Therapeutics Positive EXACT Phase 2 Data for Lead Candidate XC001 Simultaneously Presented at Society for Cardiovascular Angiography & Interventions (SCAI) 2024 Scientific Sessions and Published in Circulation: Cardiovascular Interventions
WAYNE, Pa.--(BUSINESS WIRE)--XyloCor Therapeutics, Inc., a clinical‑stage biopharmaceutical company developing novel gene therapies for cardiovascular disease, today presented final results from the Phase 2 portion of its Phase 1/2 clinical trial (EXACT) of its lead gene therapy candidate XC001 (encoberminogene rezmadenovec) for refractory angina at the Society for Cardiovascular Angiography & Interventions (SCAI) 2024 Scientific Sessions, May 2-4, 2024 in Long Beach, CA. These encouragingXyloCor Therapeutics Presents Phase 2 Data Highlighting Safety and Efficacy of XC001 at the European Society of Cardiology (ESC) Congress 2023
WAYNE, PA.--(BUSINESS WIRE)--XyloCor Therapeutics, Inc., a clinical‑stage biopharmaceutical company developing novel gene therapies for cardiovascular disease, today presented results from the Phase 2 portion of its Phase 1/2 clinical trial (EXACT) of its lead gene therapy candidate XC001 (encoberminogene rezmadenovec) for refractory angina at the European Society of Cardiology (ESC) Congress 2023. During the ESC Congress poster session, Dr. Thomas Povsic, Principal Investigator of the EXACT tr
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding XyloCor Therapeutics
Sign Up For FreeTo access detailed company insights
XyloCor Therapeutics is a biopharmaceutical company focused on the development of novel gene therapy for unmet needs in advanced coronary artery disease. Established in 2013, XyloCor Therapeutics is headquartered in Pennsylvania, United States.... Read More
